India, April 8 -- Wedbush analysts on Wednesday reiterated Viridian Therapeutics (VRDN) at Outperform rating but trimmed the price target to $31 from $37.
Viridian Therapeutics discovers, develops, and commercialises treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug and Elegrobart.
Published by HT Digital Content Services with permission from RTT News....